ALX Oncology Holdings Inc.
NASDAQ:ALXOBiotechnology
-$0.03 today
- Market cap
- $134.14M
- Beta
- 0.45
- P/E (TTM)
- -0.9
- EPS (TTM)
- -$1.64
Volume 0.56M
Average 1.07M
ALXO Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
ALX Oncology Holdings Inc.NASDAQ: ALXO
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $2.51M fell 51.9% year over year, ahead of the -60.9% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 7.3% from the prior quarter. Over 3 fiscal years it compounded at -19.2% a year.
Context
- Stock-based compensation increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -51.9% holds above the trailing-twelve-month pace of -60.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 12.58M USD
- Year-over-year change
- -53.6%
- 4-year CAGR
- -2.5%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 12.58M | -53.6% |
| FY2024 | 2024-12-31 | 27.09M | +3.1% |
| FY2023 | 2023-12-31 | 26.27M | +10.2% |
| FY2022 | 2022-12-31 | 23.84M | +71.3% |
| FY2021 | 2021-12-31 | 13.91M | — |
Stock-Based Compensation vs competitors
How ALXO compares with its peers on the latest reported figures
- ALXO's LTM Mar 2026 stock-based compensation of $9.87M is the 6th largest of the 8 companies compared; the peer median is $15.5M.
- Its year-over-year change of -60.9% is the 7th highest of 8, against a peer median of -21.9%.
- Over three fiscal years its annual growth of -19.2% compares with a peer median of +12.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $65.2M | +11.7% | +19.1% | 62.1% | |
| LTM Mar 2026 | $26.2M | -9.4% | +12.2% | 81.7% | |
| LTM Mar 2026 | $19.52M | +5.2% | +17.4% | 45.4% | |
| LTM Mar 2026 | $15.5M | -21.9% | -3.9% | — | |
| LTM Mar 2026 | $11.51M | -28.1% | +4.4% | 5116.0% | |
| LTM Mar 2026 | $9.87M | -60.9% | -19.2% | — | |
| LTM Mar 2026 | $7.62M | -49.8% | -20.2% | — | |
| LTM Mar 2026 | $2.68M | -107.0% | +13.8% | 4.2% | |
| Peer median (excluding ALXO) | $15.5M | -21.9% | +12.2% | 62.1% | |
Competitors are the stored peer set for ALXO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (83.46M) | (123.48M) | (160.81M) | (134.85M) | (101.7M) |
| Depreciation & Amortization | 51K | 342K | 836K | 872K | 706K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 13.91M | 23.84M | 26.27M | 27.09M | 12.58M |
| Change in Working Capital | (4.03M) | 9.85M | 8.3M | (12.43M) | 336K |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 3.29M | 4.51M | 458K | (4.02M) | 421K |
| Other Working Capital | (7.32M) | 5.34M | 7.84M | (8.41M) | (85K) |
| Other Non-Cash Items | 5.42M | 228K | (4.97M) | (2.6M) | 3.93M |
| Operating Cash Flow | (68.1M) | (89.22M) | (130.36M) | (121.91M) | (84.14M) |
| Capital Expenditures | (4.92M) | (1.43M) | (1.27M) | (447K) | (212K) |
| Acquisitions (Net) | 0 | 233.99K | 0 | 0 | 0 |
| Purchases of Investments | 0 | (376.79M) | (246.63M) | (107.41M) | (51.59M) |
| Sales of Investments | 0 | 142.8M | 292.56M | 194.11M | 134.39M |
| Other Investing Activities | 0 | (233.99K) | 0 | 0 | 0 |
| Investing Cash Flow | (4.92M) | (235.42M) | 44.66M | 86.26M | 82.59M |
| Debt Repayment | (281K) | 9.61M | (388K) | (827K) | (1.36M) |
| Common Stock Issued | 2.75M | 903K | 58.89M | 31.64M | 1.73M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (655K) | 792K | 0 | 0 |
| Financing Cash Flow | 2.47M | 9.86M | 59.29M | 30.82M | 362K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (70.55M) | (314.78M) | (26.42M) | (4.84M) | (1.19M) |
| Free Cash Flow | (73.02M) | (90.65M) | (131.64M) | (122.36M) | (84.35M) |
ALX Oncology Holdings Inc.
NASDAQ:ALXO
Intrinsic Alpha fair value
Locked
Current Price
$0.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.